These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 22460557)

  • 1. Endogenous nitric oxide synthase inhibitors in the biology of disease: markers, mediators, and regulators?
    Caplin B; Leiper J
    Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1343-53. PubMed ID: 22460557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway.
    Vallance P; Leiper J
    Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1023-30. PubMed ID: 15105281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases.
    Leiper J; Vallance P
    Cardiovasc Res; 1999 Aug; 43(3):542-8. PubMed ID: 10690326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DDAH says NO to ADMA.
    Cooke JP; Ghebremariam YT
    Arterioscler Thromb Vasc Biol; 2011 Jul; 31(7):1462-4. PubMed ID: 21677286
    [No Abstract]   [Full Text] [Related]  

  • 5. Endogenous nitric oxide synthase inhibitors are responsible for the L-arginine paradox.
    Tsikas D; Böger RH; Sandmann J; Bode-Böger SM; Frölich JC
    FEBS Lett; 2000 Jul; 478(1-2):1-3. PubMed ID: 10922458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The biology and therapeutic potential of the DDAH/ADMA pathway.
    Arrigoni F; Ahmetaj B; Leiper J
    Curr Pharm Des; 2010; 16(37):4089-102. PubMed ID: 21247398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine.
    Hu X; Atzler D; Xu X; Zhang P; Guo H; Lu Z; Fassett J; Schwedhelm E; Böger RH; Bache RJ; Chen Y
    Arterioscler Thromb Vasc Biol; 2011 Jul; 31(7):1540-6. PubMed ID: 21493890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets?
    Rochette L; Lorin J; Zeller M; Guilland JC; Lorgis L; Cottin Y; Vergely C
    Pharmacol Ther; 2013 Dec; 140(3):239-57. PubMed ID: 23859953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The DDAH-ADMA-NOS pathway.
    Leiper JM
    Ther Drug Monit; 2005 Dec; 27(6):744-6. PubMed ID: 16404814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraplatelet L-Arginine-Nitric Oxide Metabolic Pathway: From Discovery to Clinical Implications in Prevention and Treatment of Cardiovascular Disorders.
    Gawrys J; Gajecki D; Szahidewicz-Krupska E; Doroszko A
    Oxid Med Cell Longev; 2020; 2020():1015908. PubMed ID: 32215167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The biochemistry, measurement and current clinical significance of asymmetric dimethylarginine.
    Blackwell S
    Ann Clin Biochem; 2010 Jan; 47(Pt 1):17-28. PubMed ID: 19940201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ADMA: its role in vascular disease.
    Cooke JP
    Vasc Med; 2005 Jul; 10 Suppl 1():S11-7. PubMed ID: 16444864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney.
    Tojo A; Welch WJ; Bremer V; Kimoto M; Kimura K; Omata M; Ogawa T; Vallance P; Wilcox CS
    Kidney Int; 1997 Dec; 52(6):1593-601. PubMed ID: 9407505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis.
    Leiper J; Nandi M
    Nat Rev Drug Discov; 2011 Apr; 10(4):277-91. PubMed ID: 21455237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of asymmetric dimethylarginine (ADMA) on heart failure development.
    Liu X; Hou L; Xu D; Chen A; Yang L; Zhuang Y; Xu Y; Fassett JT; Chen Y
    Nitric Oxide; 2016 Apr; 54():73-81. PubMed ID: 26923818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).
    Maas R
    Vasc Med; 2005 Jul; 10 Suppl 1():S49-57. PubMed ID: 16444869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biological and pathophysiological roles of endogenous methylarginines as inhibitors of nitric oxide synthase].
    Masuda H; Azuma H
    Nihon Yakurigaku Zasshi; 2002 Jan; 119(1):29-35. PubMed ID: 11862754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase.
    Leiper J; Murray-Rust J; McDonald N; Vallance P
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13527-32. PubMed ID: 12370443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology and clinical pharmacology of methylarginines used as inhibitors of nitric oxide synthases.
    Kittel A; Maas R
    Curr Pharm Des; 2014; 20(22):3530-47. PubMed ID: 24180385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous production of nitric oxide synthase inhibitors.
    Anthony S; Leiper J; Vallance P
    Vasc Med; 2005 Jul; 10 Suppl 1():S3-9. PubMed ID: 16444863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.